Circulation and Molecular Epidemiology of Enteroviruses in Paralyzed, Immunodeficient and Healthy Individuals in Tunisia, a Country with a Polio-Free Status for Decades.
Picornaviridae
VDPV
acute flaccid paralysis
epidemiology
nonpolio enterovirus
poliovirus
primary immunodeficiencies
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
27 02 2021
27 02 2021
Historique:
received:
03
02
2021
revised:
17
02
2021
accepted:
20
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
17
8
2021
Statut:
epublish
Résumé
This report is an overview of enterovirus (EV) detection in Tunisian polio-suspected paralytic cases (acute flaccid paralysis (AFP) cases), healthy contacts and patients with primary immunodeficiencies (PID) during an 11-year period. A total of 2735 clinical samples were analyzed for EV isolation and type identification, according to the recommended protocols of the World Health Organization. Three poliovirus (PV) serotypes and 28 different nonpolio enteroviruses (NPEVs) were detected. The NPEV detection rate was 4.3%, 2.8% and 12.4% in AFP cases, healthy contacts and PID patients, respectively. The predominant species was EV-B, and the circulation of viruses from species EV-A was noted since 2011. All PVs detected were of Sabin origin. The PV detection rate was higher in PID patients compared to AFP cases and contacts (6.8%, 1.5% and 1.3% respectively). PV2 was not detected since 2015. Using nucleotide sequencing of the entire VP1 region, 61 strains were characterized as Sabin-like. Among them, six strains of types 1 and 3 PV were identified as pre-vaccine-derived polioviruses (VDPVs). Five type 2 PV, four strains belonging to type 1 PV and two strains belonging to type 3 PV, were classified as iVDPVs. The data presented provide a comprehensive picture of EVs circulating in Tunisia over an 11-year period, reveal changes in their epidemiology as compared to previous studies and highlight the need to set up a warning system to avoid unnoticed PVs.
Identifiants
pubmed: 33673590
pii: v13030380
doi: 10.3390/v13030380
pmc: PMC7997211
pii:
doi:
Substances chimiques
Poliovirus Vaccine, Oral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Sci Rep. 2014 Aug 22;4:6167
pubmed: 25145609
J Clin Microbiol. 2012 May;50(5):1650-8
pubmed: 22337981
Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):3078-3083
pubmed: 29507246
Clin Vaccine Immunol. 2014 Jul;21(7):1012-8
pubmed: 24850620
Annu Rev Microbiol. 2005;59:587-635
pubmed: 16153180
Jpn J Infect Dis. 2018 Nov 22;71(6):442-447
pubmed: 30068885
J Clin Virol. 2015 Aug;69:7-11
pubmed: 26209368
Proc Natl Acad Sci U S A. 1982 Oct;79(19):5793-7
pubmed: 6310545
Infect Genet Evol. 2011 Mar;11(2):276-89
pubmed: 20615482
Euro Surveill. 2016 Sep 29;21(39):
pubmed: 27719752
J Virol. 1999 Mar;73(3):1941-8
pubmed: 9971773
J Clin Virol. 2016 Aug;81:90-3
pubmed: 27367546
J Gen Virol. 2013 Sep;94(Pt 9):2017-2028
pubmed: 23804569
Euro Surveill. 2016 Sep 29;21(39):
pubmed: 27719751
Open Forum Infect Dis. 2018 Oct 01;5(10):ofy250
pubmed: 30377626
J Virol. 1991 Mar;65(3):1377-82
pubmed: 1847458
Infect Genet Evol. 2015 Mar;30:244-248
pubmed: 25562123
J Infect Dis. 1997 Feb;175 Suppl 1:S117-21
pubmed: 9203703
Handb Clin Neurol. 2014;123:379-416
pubmed: 25015496
MMWR Morb Mortal Wkly Rep. 2005 Sep 30;54(38):958-61
pubmed: 16195695
Infect Genet Evol. 2013 Mar;14:282-93
pubmed: 23201849
Infect Genet Evol. 2013 Jun;16:234-47
pubmed: 23462388
Appl Environ Microbiol. 2012 Oct;78(19):6946-53
pubmed: 22843520
J Gen Virol. 2017 Oct;98(10):2421-2422
pubmed: 28884666
PLoS Pathog. 2015 Aug 27;11(8):e1005114
pubmed: 26313548
J Med Virol. 2004 Feb;72(2):268-74
pubmed: 14695669
MMWR Morb Mortal Wkly Rep. 2017 Jun 23;66(24):649-652
pubmed: 28640795
Eur J Pediatr. 1989 Jun;148(7):642-3
pubmed: 2545452
Sci Rep. 2017 Jun 19;7(1):3808
pubmed: 28630462
J Gen Virol. 2017 Dec;98(12):2968-2981
pubmed: 29095688
J Med Virol. 2012 Apr;84(4):624-31
pubmed: 22337302
BMC Infect Dis. 2007 Feb 15;7:6
pubmed: 17300736
J Clin Virol. 2018 Apr;101:11-17
pubmed: 29414181
MMWR Morb Mortal Wkly Rep. 2015 Jul 3;64(25):699-702
pubmed: 26135591
J Clin Microbiol. 2000 Mar;38(3):1170-4
pubmed: 10699015
J Med Microbiol. 2006 Aug;55(Pt 8):1035-1041
pubmed: 16849723
Springerplus. 2016 Feb 24;5:158
pubmed: 27026855
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
Rev Infect Dis. 1987 Mar-Apr;9(2):334-56
pubmed: 3296100
Eur J Clin Microbiol Infect Dis. 2009 Jun;28(6):683-7
pubmed: 19130106
J Med Virol. 2017 Sep;89(9):1550-1558
pubmed: 28071799
MMWR Morb Mortal Wkly Rep. 2018 Jun 22;67(24):690-694
pubmed: 29927908
MMWR Morb Mortal Wkly Rep. 2016 May 13;65(18):470-3
pubmed: 27171208
J Med Microbiol. 2005 Jan;54(Pt 1):63-69
pubmed: 15591257
BMJ Case Rep. 2009;2009:
pubmed: 21686352
J Clin Microbiol. 1999 May;37(5):1288-93
pubmed: 10203472
J Clin Virol. 2008 Feb;41(2):81-6
pubmed: 18023246